The article concludes that for technology transfer through PDPs to be meaningful, the right indices must be put in place to encourage local production. Part five, describes in a game-theoretic setting, that while the mode of TT is influenced by IPRs, with internalization through foreign direct investment (FDI), the chosen path in third world countries with fragile patent systems, the quality of technology transferred is influenced with stronger IPRs. Since the methodology adopted is that of a case study, part three analyses five different PDPs to see how they deal or rather manage IP issues that arise in their various drug development pipeline as different PDPs deal with technology transfer matters on a case by case basis as they have their own documents or commitment of technology transfer with different developing country parties. The article proceeds in the following manner, while the first part provides background information on PDPs, the second part, discusses the relationship between transfer of technology and local production. The improvement of the enforcement of the administrative, civil and penal regulations is imperative. The challenge for governments is to improve the chain of responsibilities to protect the pharmaceuticals market. An effective intellectual property system provide fair and efficient incentives for innovation. If we want better medicines, the patent system is the way to encourage it. The protection of intellectual property rights is interlinked with the protection from illegal medicines trade and a fundamental issue for the pharmaceutical sector and the patients. Governments on their part should strengthen their controls to detect illegal medicines. It corresponds to the administrative, civil and criminal law to define the different problems and establish the corresponding penalties. In order to prevent the presence in the market of illegal products is necessary a global approach to define the scope of the problem and the measures to be put in place. All of which breach different provisions of the pharmaceutical legislation and could be appropriately qualified as illegal. The transgressions of the rules that govern the distribution and marketing of medicinal products comes in many different forms, including substandard medicines, falsified drugs, counterfeits, ineffective medicines, falsely-labelled medicines and unregistered medicines. The trade in illegal pharmaceuticals is a global problem for public health. The Roundtable proceedings included presentations on all participants' areas of expertize, reflections across The need for such a discussion was the primary reason for convening the Roundtable. The multidisciplinary nature of the problem of access to medicines in LICs requires a holistic approach, especially one that identifies and examines the areas where cross-disciplinary collaboration is valuable. The paper concludes by identifying areas warranting further research. Finally, the paper examines mechanisms for improving the obtainability of medicines in LICs, through low-cost intervention, task-shifting, efficient regulation, grassroots service provision and education. Next, the paper reviews mechanisms for improving the efficacy of medicines in LICs, including authentication, criminalization, international and national enforcement and communication and education. The paper then assesses mechanisms for improving affordability of medicines in LICs, such as differential pricing mechanisms, monopsonies, patent law flexibilities and human rights obligations. It first considers mechanisms for improving the availability of medicines in LICs, through grants, prizes, treaties, advance market commitments, priority review and product development partnerships to incentivize and fund R&D for neglected diseases. Whereas, other writings on the topic tend to focus on one or a small number of issues, often from the perspective of a single discipline, this paper seeks to consider the major issues from a multidisciplinary perspective. The multidisciplinary nature of this problem requires a holistic approach. Individuals in low-income countries ("LICs") often lack access to appropriate medicines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |